HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Vernon E Steele Selected Research

Eflornithine (Ornidyl)

11/2016Potentiating NK cell activity by combination of Rosuvastatin and Difluoromethylornithine for effective chemopreventive efficacy against Colon Cancer.
12/2014Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling.
2/2014Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model.
5/2013Multitargeted low-dose GLAD combination chemoprevention: a novel and promising approach to combat colon carcinogenesis.
2/2007Development and characteristics of a human cell assay for screening agents for melanoma prevention.
10/2004Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Vernon E Steele Research Topics

Disease

106Neoplasms (Cancer)
11/2021 - 05/2002
49Carcinogenesis
01/2019 - 05/2002
23Adenoma (Adenomas)
11/2021 - 07/2002
21Colonic Neoplasms (Colon Cancer)
11/2021 - 01/2002
21Body Weight (Weight, Body)
01/2018 - 01/2002
19Breast Neoplasms (Breast Cancer)
01/2019 - 01/2002
14Adenocarcinoma
11/2021 - 05/2005
13Carcinoma (Carcinomatosis)
11/2021 - 07/2002
13Lung Neoplasms (Lung Cancer)
01/2019 - 02/2003
11Aberrant Crypt Foci
01/2014 - 02/2005
8Inflammation (Inflammations)
10/2017 - 05/2010
8Urinary Bladder Neoplasms (Bladder Cancer)
02/2014 - 03/2005
7Carcinoma in Situ
11/2017 - 11/2010
7Pancreatic Neoplasms (Pancreatic Cancer)
01/2016 - 11/2010
6Prostatic Neoplasms (Prostate Cancer)
03/2010 - 09/2002
4Colorectal Neoplasms (Colorectal Cancer)
11/2021 - 01/2009
4Hyperplasia
12/2016 - 01/2013
4Polyps
05/2013 - 07/2006
3Lung Diseases (Lung Disease)
12/2016 - 09/2009
3Intestinal Polyps
01/2014 - 07/2006
2Squamous Cell Carcinoma of Head and Neck
01/2015 - 01/2010
2Mouth Neoplasms (Oral Cancer)
01/2015 - 01/2010

Drug/Important Bio-Agent (IBA)

26Biomarkers (Surrogate Marker)IBA
01/2020 - 07/2002
21AzoxymethaneIBA
11/2021 - 02/2004
20SmokeIBA
10/2017 - 10/2007
15CarcinogensIBA
11/2021 - 05/2002
14Methylnitrosourea (N-Methyl-N-nitrosourea)IBA
03/2015 - 01/2002
13Pharmaceutical PreparationsIBA
01/2020 - 03/2007
13MicroRNAs (MicroRNA)IBA
10/2017 - 03/2009
10Proliferating Cell Nuclear Antigen (PCNA)IBA
11/2019 - 07/2002
10Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA
10/2017 - 12/2003
10Bexarotene (LGD1069)FDA Link
12/2013 - 02/2005
10vinyl carbamateIBA
09/2012 - 07/2002
9Budesonide (Pulmicort)FDA LinkGeneric
01/2019 - 07/2002
9Proteins (Proteins, Gene)FDA Link
12/2013 - 09/2002
8Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
11/2019 - 02/2004
8Naproxen (Naprosyn)FDA LinkGeneric
11/2019 - 11/2009
8Gefitinib (Iressa)FDA Link
01/2019 - 04/2008
8hydroxide ionIBA
10/2018 - 03/2005
8DNA (Deoxyribonucleic Acid)IBA
06/2014 - 02/2004
8Messenger RNA (mRNA)IBA
09/2012 - 09/2002
7Estrogens (Estrogen)FDA Link
12/2016 - 07/2006
7licofeloneIBA
01/2016 - 08/2011
7Celecoxib (Celebrex)FDA Link
01/2015 - 10/2004
6Benzo(a)pyreneIBA
01/2019 - 05/2003
6Eflornithine (Ornidyl)FDA Link
11/2016 - 10/2004
6Cyclooxygenase 2 (Cyclooxygenase-2)IBA
12/2015 - 07/2006
6Arachidonate 5-Lipoxygenase (5 Lipoxygenase)IBA
10/2015 - 01/2010
6Atorvastatin (Lipitor)FDA Link
05/2013 - 04/2006
5Metformin (Glucophage)FDA LinkGeneric
01/2020 - 12/2013
5Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
11/2016 - 04/2006
5ErbB Receptors (EGF Receptor)IBA
10/2015 - 04/2008
5Estrogen ReceptorsIBA
03/2015 - 10/2004
4Caspase 3 (Caspase-3)IBA
11/2019 - 03/2007
4Pioglitazone (Actos)FDA Link
02/2017 - 10/2013
4Cyclin D1IBA
01/2016 - 03/2008
4NitrosaminesIBA
02/2014 - 11/2008
4SurvivinIBA
01/2012 - 03/2005
4AndrogensIBA
03/2010 - 09/2006
4FenretinideIBA
02/2007 - 01/2002
4tipifarnib (R115777)IBA
01/2007 - 05/2003
4RetinoidsIBA
07/2006 - 09/2002
4AlitretinoinFDA Link
02/2004 - 05/2002
3Omeprazole (Prilosec)FDA LinkGeneric
11/2021 - 01/2012
3Proton Pump InhibitorsIBA
11/2021 - 01/2012
3Lapatinib (GW572016)FDA Link
01/2019 - 10/2014
3GlucocorticoidsIBA
01/2019 - 12/2006
3Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA
10/2017 - 06/2006
3PolyaminesIBA
11/2016 - 12/2014
3Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
02/2016 - 12/2011
3CateninsIBA
10/2015 - 05/2013
3AntioxidantsIBA
06/2014 - 08/2009
3Sulindac (Copal)FDA LinkGeneric
02/2014 - 09/2002
3ProstaglandinsIBA
01/2013 - 05/2005
3salicylhydroxamic acid (SHAM)IBA
01/2013 - 12/2008
3phenethyl isothiocyanate (PEITC)IBA
05/2010 - 06/2009
3Piroxicam (Feldene)FDA LinkGeneric
01/2010 - 09/2002
3TransferasesIBA
01/2007 - 04/2006
3Biological ProductsIBA
02/2004 - 07/2002
2AcidsIBA
11/2021 - 01/2014
2Hypoglycemic Agents (Hypoglycemics)IBA
01/2020 - 12/2013
2Drug CombinationsIBA
01/2020 - 02/2017
2Dinoprostone (PGE2)FDA Link
11/2019 - 06/2006
2AerosolsIBA
01/2019 - 02/2017
2Ethanol (Ethyl Alcohol)IBA
12/2016 - 05/2011
2Insulin (Novolin)FDA Link
03/2015 - 10/2002
2Rosiglitazone (Avandia)FDA Link
01/2015 - 11/2008
24-Nitroquinoline-1-oxide (4 Nitroquinoline 1 oxide)IBA
01/2015 - 01/2010
2Anti-Inflammatory Agents (Anti-Inflammatories)IBA
01/2015 - 02/2003
2EnzymesIBA
12/2014 - 02/2003
2Complex MixturesIBA
06/2014 - 10/2007
2Histone Deacetylase InhibitorsIBA
01/2014 - 01/2013
2Insulin-Like PeptidesIBA
12/2013 - 10/2002
2Retinoid X Receptors (Retinoid X Receptor)IBA
12/2013 - 02/2009
2Phosphotransferases (Kinase)IBA
12/2013 - 08/2007
2Raloxifene Hydrochloride (Evista)FDA Link
12/2013 - 01/2009

Therapy/Procedure

39Chemoprevention
01/2019 - 08/2002
5Therapeutics
01/2014 - 05/2003
3Injections
01/2009 - 06/2006
2Aftercare (After-Treatment)
09/2018 - 10/2002